VRTX · Q2 2026 Earnings

Bullish

Vertex Pharmaceuticals

Reported August 3, 2026

30-second summary

Q2 FY2026 revenue of $3.33B grew 12% YoY, driven by CASGEVY (+78% QoQ to $76M) and JOURNAVX (+71% QoQ to $50M) accelerating faster than the back-half-weighted framing implied — enough for Vertex to raise the FY2026 revenue guide to $13.1–13.2B (midpoint +$125M, or ~1%) while reaffirming the $500M+ non-CF floor, the $5.65–5.75B non-GAAP opex range, and the 19.5–20.5% tax rate. Non-GAAP EPS came in at $4.73 and GAAP diluted EPS at $4.31, alongside a genuine guidance raise. The subtle disclosure: management now quantifies FX as ~150bps of the FY2026 growth rate — meaning organic constant-currency growth is closer to 6.5–7.5% versus the 8–9% headline.

Headline numbers

EPS

Q2 FY2026

$4.73

-0.4% vs est.

Revenue

Q2 FY2026

$3.33B

+12.0% YoY

+3.5% vs est.

Gross margin

Q2 FY2026

85.3%

Operating margin

Q2 FY2026

37.4%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$3.33B	$2.96B	+12.6%	$2.99B	+11.5%
EPS	$4.73	$4.52	+4.6%	$4.47	+5.8%
Gross margin	85.3%	86.2%	-93bps	86.9%	-160bps
Operating margin	37.4%	38.8%	-143bps	38.1%	-70bps

Guidance

Vertex raised FY2026 revenue guidance to $13.1–$13.2B (midpoint +$125M) and reaffirmed expenses and tax rate; disclosed 150 bps FX benefit to growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Foreign exchange benefit	FY2026	approximately 150 basis points	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$12.95 billion to $13.1 billion	$13.1 billion to $13.2 billion	+$150 million at low end; +$100 million at high end	Raised

Reaffirmed unchanged this quarter: Non-CF Product Revenue ($500 million or more), Combined GAAP R&D, AIPR&D and SG&A expenses ($6.3 billion to $6.45 billion), Combined non-GAAP R&D, AIPR&D and SG&A expenses ($5.65 billion to $5.75 billion), Non-GAAP effective tax rate (19.5% to 20.5%)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Cystic Fibrosis (CF) Products	$3.208B	—	+10.6%
TRIKAFTA/KAFTRIO	$2.497B	$2.55B	-2.1%
ALYFTREK	$0.574B	—	+265.4%
CASGEVY	$0.076B	—	+151.3%
JOURNAVX	$0.05B	—	+313.3%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
United States	$2.06B	$1.85B	+11.4%
Outside United States	$1.28B	—	+14.0%
CASGEVY Sequential Growth (Q1 to Q2)	78% quarter-over-quarter	—	—
JOURNAVX Sequential Growth (Q1 to Q2)	71% quarter-over-quarter	—	—
JOURNAVX Prescriptions (Q2 YTD)	~900,000 prescriptions for first six months of 2026	—	—
JOURNAVX Medicare Part D Coverage	3 of 4 major PBMs; 23 states Medicaid; ~260 million individuals with reimbursed access	—	—
ALYFTREK Reimbursement	25 countries with reimbursement; Canada letter of intent signed	—	—
CASGEVY Geographic Approvals	39 countries approved (North America, Europe, Middle East); FDA approval in children 2+ years	—	—
Operating Margin (GAAP)	37.4%	—	—
Non-GAAP Operating Margin	42.7%	44.7%	—

Management tone

Q3 FY2025 capacity expansion → Q4 FY2025 franchise reframing → Q1 FY2026 renal as filed fourth pillar → Q2 FY2026 non-CF portfolio delivering ahead of the "back-half-weighted" script

Transcript not available for Q2 FY2026; tone analysis is limited to press-release commentary and cannot be developed to Tapebrief's usual multi-quarter depth this quarter.

The back-half-weighting narrative is quietly being retired one quarter early. For three consecutive quarters management framed CASGEVY and JOURNAVX growth as explicitly H2-loaded, with "quarter-to-quarter variability" as the standard caveat. The Q2 print — CASGEVY +78% QoQ, JOURNAVX +71% QoQ — arrives against that framing and the guidance raise validates it. That the $500M+ non-CF floor was reaffirmed rather than raised despite $126M in Q2 non-CF revenue signals management is preserving room for a further raise on Q3, not that momentum has plateaued.

The FX disclosure is a small but real credibility move. Explicitly quantifying ~150bps of FX benefit in the FY guide — rather than letting the market treat the 8–9% headline as clean organic growth — is the kind of disclosure that gets rewarded on the buy-side but flagged by shorts. It tells you organic constant-currency growth in FY2026 is running mid-single-digit, and the acceleration story depends on non-CF products doing the heavy lifting in H2.

Pipeline language remains dense and specific. Povetacicept PDUFA date of November 30 anchors the renal franchise launch to a hard calendar event within 90 days of the Q3 print. Suzetrigine DPN Phase 3 enrollment completion by EOY 2026 is a reiteration. The Crinetics Pharmaceuticals acquisition (announced July: $85.00/share, ~$10.0B equity value, ~$8.8B net of cash) targeted for Q3 2026 close adds rare endocrine as the fifth pillar. None of these are new; the discipline of restating them without slippage is the tone shift.

Answers to last quarter's watch list

Q2 FY2026 revenue against the FY 8–9% YoY trajectory — Q2 printed $3.334B at +12% YoY, well above the ~$3.20B floor flagged and materially above the ~$3.22B midpoint implied by the FY guide. This removes the "H2 dependency" tail risk on FY2026 and gave management the room to raise FY guidance rather than merely reaffirm. Status: Resolved positively

JOURNAVX net revenue per Rx — Q2 implied ~$93/Rx ($49.6M revenue / ~535k disclosed Q2 Rx). Not yet at the $100+ threshold but a clear step up from Q1's ~$83, and the direction validates management's PSP taper trajectory. Reimbursed lives expanded to ~260M from ~240M at Q1 and 3 of 4 major PBMs added Medicare Part D coverage. Status: Continue monitoring

CASGEVY infusion pace — CASGEVY Q2 revenue of $76M represented +78% QoQ growth versus management's "back-half-weighted" framing — the sequential build the watch item was looking for arrived in Q2, not Q3 or Q4. FDA approval expanding to children 2+ years and 39 countries approved broaden the near-term addressable base. Status: Resolved positively

POVI IgAN BLA acceptance and PDUFA date — PDUFA date disclosed as November 30, 2026, anchoring the renal launch timing within one quarter of the next print. This resolves the timing uncertainty around the accelerated approval path flagged in Q1. Status: Resolved positively

Trikafta/Kaftrio rate of decline — Trikafta/Kaftrio printed −2.1% YoY, decelerating materially from −7.1% in Q1 and well inside the "worse than −8%" downside threshold. Combined with Alyftrek's $574M and the +10.6% YoY combined CF growth, the franchise erosion pattern is far milder than Q1 suggested. Status: Resolved positively

Combined non-CF revenue run-rate — H1 non-CF revenue of ~$198M ($72M Q1 + $126M Q2) puts Vertex on a run-rate consistent with the $500M+ FY floor, with Q2 alone at $126M implying only mid-teens sequential growth needed in H2 to clear. Both contributors accelerated sequentially in Q2 rather than staying flat as the Q1 framing implied. Status: Resolved positively

What to watch into next quarter

POVI IgAN launch execution in Q4 FY2026 — PDUFA date is November 30, 2026, placing the launch mid-Q4; watch the Q3 print for any pre-launch commercial infrastructure disclosures (field force, payer contracting) that anchor the ramp shape into 2027

JOURNAVX net revenue per Rx crossing $100 — Q2 implied ~$93/Rx; watch whether Q3 crosses the $100 threshold flagged as the PSP-normalization unlock, since sustained $100+ combined with the ~260M reimbursed lives is what makes JOURNAVX a multi-billion-dollar franchise rather than a mid-cap product

CASGEVY Q3 revenue holding above $75M — Q2 delivered $76M with +78% QoQ growth; watch whether Q3 sustains at or above this level (i.e., positive sequential rather than reversion) given management's explicit "quarter-to-quarter variability" language — a Q3 print below $60M would validate that caveat and cap FY2026 CASGEVY revenue near $250M

Second FY2026 revenue raise on Q3 print — the $500M+ non-CF floor was reaffirmed despite $198M H1 tracking; watch whether Q3 delivers a further FY revenue raise and/or a tightening of the non-CF floor (e.g., to $525M+), since management is signaling room to raise again if CASGEVY/JOURNAVX H2 momentum holds

Crinetics Pharmaceuticals acquisition close in Q3 FY2026 — management reiterated Q3 close ($85.00/share, ~$10.0B equity value, ~$8.8B net of cash); watch the Q3 print for close confirmation and any incremental disclosure on integration cost, deal-related opex, or FY2027 guidance implications following updated post-close guidance

Trikafta/Kaftrio YoY stabilization — decline improved from −7.1% (Q1) to −2.1% (Q2); watch whether Q3 holds within −3% to +1% YoY, since a return to −5%-or-worse would reopen the CF franchise erosion narrative even with Alyftrek offset

Non-GAAP ETR trajectory — Q2 non-GAAP ETR of 21.1% ran above the reaffirmed 19.5–20.5% FY range; watch whether H2 rates step down enough to land the FY inside the guide, or whether the rate range itself gets revised on Q3

FX tailwind sustainability — the new ~150bps FX disclosure ties FY guidance quality to currency; watch whether Q3 organic constant-currency growth (headline growth minus the disclosed FX contribution) accelerates from the mid-single-digit implied Q2 pace

Sources

Vertex Pharmaceuticals Q2 FY2026 press release (SEC EDGAR Ex-99.1): https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm
Vertex Pharmaceuticals Q1 FY2026 press release and Tapebrief Q1 FY2026 brief (prior quarter context, guidance baseline)
Vertex Pharmaceuticals Q4 FY2025 press release and Tapebrief Q4 FY2025 brief (FY2026 initial guidance framework)
Vertex Pharmaceuticals Q3 FY2025 and Q2 FY2025 Tapebrief briefs (cross-quarter franchise trajectory context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.